

Week 12 - Week Ending Mar 23, 2024


For the week ending Mar 23, 2103 respiratory patient specimens were submitted for Influenza A/B and Respiratory Syncytial Virus (RSV) testing.


Influenza A was detected in 148 of 2103 specimens (7%). Influenza B was detected in 125 of 2103 specimens (5.94%). RSV was detected in 28 of 2103 specimens (1.3%).





Week 12 - Week Ending Mar 23, 2024







Week 12 - Week Ending Mar 23, 2024

For the week ending Mar 23, 2518 respiratory patient specimen were submitted for COVID-19 testing.


SARS-CoV-2 was detected in 138 of 2518 specimens (5.5%).






Week 12 - Week Ending Mar 23, 2024

For the week ending Mar 23, 86 respiratory patient specimens were submitted for Human Metapneumovirus (hMPV),
Adenovirus (AdV), & Rhinovirus (RV) testing.
hMPV was detected in 3 of 86 specimens (3.5%).
AdV was detected in 4 of 86 specimens (4.7%).
RV was detected in 14 of 86 specimens (16.3%).





Week 12 - Week Ending Mar 23, 2024

For the week ending Mar 23, 76 respiratory patient specimens were submitted for Parainfluenza (PIV) testing.

PIV1 was detected in 0 of 76 specimens (0%). PIV2 was detected in 0 of 76 specimens (0%). PIV3 was detected in 4 of 76 specimens (5.3%). PIV4 was detected in 0 of 76 specimens (0%).

